SlideShare ist ein Scribd-Unternehmen logo
1 von 43
 
Sergio López Soria PCVD in 2011:  An update
Historical background of PCV2 and PCVD
Historical background ,[object Object],Edward Clark John Harding
Historical background This syndrome was characterized by: ,[object Object],[object Object],[object Object]
Historical background ,[object Object],[object Object],[object Object]
Historical background ,[object Object],[object Object],[object Object],Porcine circovirus type 2  (PCV2) Porcine circovirus  type 1 (PCV1) Genus  Circovirus PK-15 contaminant PMWS
PCV2 and PCVD
[object Object],[object Object],[object Object],[object Object],[object Object],PCV2 PCV2 www.pcvd.eu
PCV2 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],PCV2 and PCVD
1960 2009 Natural history of PCV2 and PMWS  First retrospective evidence of PCV2 infection (1962) First retrospective evidence of PMWS  occurrence (1985) First description of PMWS in NA (1991) – sporadic First description of PMWS in EU (1995-97)  Major epizootic PMWS  outbreaks in EU and  Asia (1998-2004) Major epizootic PMWS  outbreaks in North and  South America (2004-07) First PCV2 vaccine available (2004) PCV2 vaccines
PMWS distribution ,[object Object],Countries in red mean that they have described at least one case of PMWS (based on available literature) PCV2 Infection worldwide
PCV2 infection and transmission
PCV2 viral loads (qPCR)  or PCV2 antibody titres Weeks of age PCV2 antibodies PMWS PCV2 infection dynamics  1 3 7-9 21 15 PCV2 viremia
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],PCV2 horizontal transmission Oro-nasal route: principal horizontal transmission Segalés et al., 2005 PMWS Affected Wasted Non-PMWS Healthy PMWS affected pigs harbour higher PCV2 amounts in those secretions/locations
sow Boar ,[object Object],[object Object],[object Object],[object Object],Semen ,[object Object],[object Object],[object Object],PCV2 transmission by semen ,[object Object],[object Object],[object Object]
sow ,[object Object],[object Object],PCV2 vertical transmission ,[object Object],   Yes ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],sow PCV2 vertical transmission ,[object Object],[object Object],X   Unfortunately it remains unknown
[object Object],[object Object],PCV2 and PMWS horizontal transmission ,[object Object],[object Object],[object Object],   Obviously Yes    Yes
PMWS
If PCV2 is ubiquitous, ¿WHY SOME FARMS EXPERIENCE PMWS?
Pig genetics, sex, other Co-infections PCV2 genotype Moment of infection Sow status Management: Madec’s 20 point plan PMWS: a multifactorial disease
[object Object],[object Object],[object Object],[object Object],PMWS reduction through zootechnical measures Measures directed to diminish the dissemination  infectious agents and their infectious pressure
PMWS reduction through zootechnical measures (Guilmoto y Wessel-Robert, 2000) Farm Rate of measures compliance Loss rate before (%) Loss reduction 1 81% 18.3 -13.7 2 86% 14.7 -12.7 3 59% 19.0 -9.3 4 84% 11.2 -5.8 5 79% 15.3 -6.4 6 70% 12.7 -4.7 7 82% 11.5 -4.4 8 55% 12.3 -3.5 9 54% 17.6 0.4 10 72% 11.3 0.7 Media 66% 13.1 -5.4
PMWS reduction through zootechnical measures (Guilmoto y Wessel-Robert, 2000) Farm Rate of measures compliance Loss rate before (%) Loss reduction 1 81% 18.3 -13.7 2 86% 14.7 -12.7 3 59% 19.0 -9.3 4 84% 11.2 -5.8 5 79% 15.3 -6.4 6 70% 12.7 -4.7 7 82% 11.5 -4.4 8 55% 12.3 -3.5 9 54% 17.6 0.4 10 72% 11.3 0.7 Media 66% 13.1 -5.4
PMWS reduction through zootechnical measures (Guilmoto y Wessel-Robert, 2000) ,[object Object],[object Object],[object Object],Farm Rate of measures compliance Loss rate before (%) Loss reduction 1 81% 18.3 -13.7 2 86% 14.7 -12.7 3 59% 19.0 -9.3 4 84% 11.2 -5.8 5 79% 15.3 -6.4 6 70% 12.7 -4.7 7 82% 11.5 -4.4 8 55% 12.3 -3.5 9 54% 17.6 0.4 10 72% 11.3 0.7 Media 66% 13.1 -5.4
[object Object],“ Sow effect ” Calsamiglia et al., 2007 Sibila et al., 2004 ,[object Object],Factors related to PMWS development ,[object Object],[object Object],[object Object],[object Object],0 50 100 PCV2 prevalence Weeks of age 1-5 PMWS affected farms Non-PMWS affected farms 6-10 11-15 16-20 21-25
[object Object],Factors related to PMWS development: The PCV2 genotype Experimental infections 50% PMWS with “b” (20 studies) 35% PMWS with “a” (75 studies) PMWS with “b” 3,45 times > “a” (Tomás et al., 2008)
PCV2 subclinical infection
PCV2 subclinical infection 160 piglets from two PMWS affected farms. Weight and viral load analyses at 3, 9, 15 and 21 wks of age. Area under the curve for weight and viral load was calculated. The higher the AUCqPCR during the postweaning period, the lower AUCW (ρ=-0.203; p=0.010).
Laboratorial Techniques for PCV2 and PMWS
PCR Laboratorial Analyses: PCR Useful to monitor: Infection dynamic Subclinical infection Sibila et al., 2004 % PCR (serum) Weeks of age  Non-PMWS affected farms Percentage PMWS affected farms PCV2 is ubiquitous Not useful for PMWS diagnosis
Can PMWS be diagnosed in live animals??? Laboratorial Analyses: qPCR Quantitative PCR Slight Moderate Severe PMWS lesions a b c Olvera et al., 2004 PMWS Subclinical PCV2 infection
Not proved to be specific and/or sensitive enough to replace current diagnostic criteria  (Fort et al., 2007; Grau-Roma et al., 2009) Inter-laboratory and inter-assay variation  (Harding et al., 2009; Hjulsager et al., 2009) qPCR suggested  applications for PMWS herd diagnosis. Can qPCR be used as a diagnostic tool for PMWS?
Non-PMWS affected farms Weeks of age PMWS affected farms Serology   (IPMA, ELISA) Sibila et al., 2004 Percentage Laboratorial Analyses: Serology Useful to monitor: Maternal immunity transfer Infection dynamic Seroconversion to vaccination PCV2 is ubiquitous All piglets seroconvert Not useful for PMWS diagnosis
[object Object],[object Object],[object Object],[object Object],(Sorden, 2000; Segalés, 2002) PMWS diagnosis H/E PCV2 ISH
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Laboratorial Analyses: Sample collection for histopathology Non essential for PMWS diagnosis
Prevention and control
Prevention and control Prevention and control Initial efforts directed to counteract the known triggering factors Since 2004 onwards    PCV2 vaccination
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Prevention and control Is PCV2 vaccination the solution for PMWS and PCV2 subclinical infection?
PCV2 CReSA Team
 

Weitere ähnliche Inhalte

Was ist angesagt?

Role of Bioinformatics in COVID 19
Role of Bioinformatics in COVID 19Role of Bioinformatics in COVID 19
Role of Bioinformatics in COVID 19mah noor
 
Aeras schofield 21112013
Aeras schofield 21112013Aeras schofield 21112013
Aeras schofield 21112013AerasGlobalTB
 
Analysis of the role of mucosal antibodies in protection against contagious c...
Analysis of the role of mucosal antibodies in protection against contagious c...Analysis of the role of mucosal antibodies in protection against contagious c...
Analysis of the role of mucosal antibodies in protection against contagious c...ILRI
 
疫苗研發之產學研合作經驗分享 以冠狀病毒奈米疫苗為例
疫苗研發之產學研合作經驗分享以冠狀病毒奈米疫苗為例疫苗研發之產學研合作經驗分享以冠狀病毒奈米疫苗為例
疫苗研發之產學研合作經驗分享 以冠狀病毒奈米疫苗為例hprc_tmu
 
COVID 19 Búsqueda - Dr. Freddy Flores Malpartida
COVID 19 Búsqueda - Dr. Freddy Flores MalpartidaCOVID 19 Búsqueda - Dr. Freddy Flores Malpartida
COVID 19 Búsqueda - Dr. Freddy Flores MalpartidaFreddy Flores Malpartida
 
El medicamento aprobado por la FDA ivermectina
El medicamento aprobado por la FDA ivermectinaEl medicamento aprobado por la FDA ivermectina
El medicamento aprobado por la FDA ivermectinaDanielErnestoEscobar
 
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild ...
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild ...Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild ...
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild ...Guy Boulianne
 
an mrna vaccine aganist sars cov 2
an mrna vaccine aganist sars cov 2 an mrna vaccine aganist sars cov 2
an mrna vaccine aganist sars cov 2 antomathew8
 
Presentation 18: Problems other than AHPND in EMS ponds, including the micros...
Presentation 18: Problems other than AHPND in EMS ponds, including the micros...Presentation 18: Problems other than AHPND in EMS ponds, including the micros...
Presentation 18: Problems other than AHPND in EMS ponds, including the micros...ExternalEvents
 
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...Rafael Monleon
 
2.4 jean-michel pawlotsky
2.4 jean-michel pawlotsky2.4 jean-michel pawlotsky
2.4 jean-michel pawlotskyAssociation LIR
 
SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination I...
SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination I...SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination I...
SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination I...Guy Boulianne
 
Cacoub hcv ehm & inflam du16
Cacoub hcv ehm & inflam du16  Cacoub hcv ehm & inflam du16
Cacoub hcv ehm & inflam du16 odeckmyn
 
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine ...
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine ...Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine ...
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine ...Guy Boulianne
 
Preprint book rbd targeted covid vaccine and full length spike protein vacc...
Preprint  book  rbd targeted covid vaccine and full length spike protein vacc...Preprint  book  rbd targeted covid vaccine and full length spike protein vacc...
Preprint book rbd targeted covid vaccine and full length spike protein vacc...M. Luisetto Pharm.D.Spec. Pharmacology
 
J. Virol.-2012-Qureshi-2239-50
J. Virol.-2012-Qureshi-2239-50J. Virol.-2012-Qureshi-2239-50
J. Virol.-2012-Qureshi-2239-50Huma Qureshi
 

Was ist angesagt? (20)

Publication 3 - 3rd Author
Publication 3 - 3rd AuthorPublication 3 - 3rd Author
Publication 3 - 3rd Author
 
Resoso PRRS
Resoso PRRSResoso PRRS
Resoso PRRS
 
Role of Bioinformatics in COVID 19
Role of Bioinformatics in COVID 19Role of Bioinformatics in COVID 19
Role of Bioinformatics in COVID 19
 
Aeras schofield 21112013
Aeras schofield 21112013Aeras schofield 21112013
Aeras schofield 21112013
 
Journal Pre-Proof
Journal Pre-ProofJournal Pre-Proof
Journal Pre-Proof
 
Analysis of the role of mucosal antibodies in protection against contagious c...
Analysis of the role of mucosal antibodies in protection against contagious c...Analysis of the role of mucosal antibodies in protection against contagious c...
Analysis of the role of mucosal antibodies in protection against contagious c...
 
fadyia
fadyiafadyia
fadyia
 
疫苗研發之產學研合作經驗分享 以冠狀病毒奈米疫苗為例
疫苗研發之產學研合作經驗分享以冠狀病毒奈米疫苗為例疫苗研發之產學研合作經驗分享以冠狀病毒奈米疫苗為例
疫苗研發之產學研合作經驗分享 以冠狀病毒奈米疫苗為例
 
COVID 19 Búsqueda - Dr. Freddy Flores Malpartida
COVID 19 Búsqueda - Dr. Freddy Flores MalpartidaCOVID 19 Búsqueda - Dr. Freddy Flores Malpartida
COVID 19 Búsqueda - Dr. Freddy Flores Malpartida
 
El medicamento aprobado por la FDA ivermectina
El medicamento aprobado por la FDA ivermectinaEl medicamento aprobado por la FDA ivermectina
El medicamento aprobado por la FDA ivermectina
 
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild ...
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild ...Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild ...
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild ...
 
an mrna vaccine aganist sars cov 2
an mrna vaccine aganist sars cov 2 an mrna vaccine aganist sars cov 2
an mrna vaccine aganist sars cov 2
 
Presentation 18: Problems other than AHPND in EMS ponds, including the micros...
Presentation 18: Problems other than AHPND in EMS ponds, including the micros...Presentation 18: Problems other than AHPND in EMS ponds, including the micros...
Presentation 18: Problems other than AHPND in EMS ponds, including the micros...
 
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
Occurrence and Distribution of Transmissible Viral Proventriculitis in North ...
 
2.4 jean-michel pawlotsky
2.4 jean-michel pawlotsky2.4 jean-michel pawlotsky
2.4 jean-michel pawlotsky
 
SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination I...
SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination I...SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination I...
SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination I...
 
Cacoub hcv ehm & inflam du16
Cacoub hcv ehm & inflam du16  Cacoub hcv ehm & inflam du16
Cacoub hcv ehm & inflam du16
 
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine ...
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine ...Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine ...
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine ...
 
Preprint book rbd targeted covid vaccine and full length spike protein vacc...
Preprint  book  rbd targeted covid vaccine and full length spike protein vacc...Preprint  book  rbd targeted covid vaccine and full length spike protein vacc...
Preprint book rbd targeted covid vaccine and full length spike protein vacc...
 
J. Virol.-2012-Qureshi-2239-50
J. Virol.-2012-Qureshi-2239-50J. Virol.-2012-Qureshi-2239-50
J. Virol.-2012-Qureshi-2239-50
 

Ähnlich wie 01 sergio lopez soria

Hiv aids general consideration bangladesh and international prospective new
Hiv aids general consideration  bangladesh and international prospective newHiv aids general consideration  bangladesh and international prospective new
Hiv aids general consideration bangladesh and international prospective newHome
 
Emerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
Emerging Viral Risks and Mitigation Strategies in Biologics ManufacturingEmerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
Emerging Viral Risks and Mitigation Strategies in Biologics ManufacturingMilliporeSigma
 
Emerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
Emerging Viral Risks and Mitigation Strategies in Biologics ManufacturingEmerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
Emerging Viral Risks and Mitigation Strategies in Biologics ManufacturingMerck Life Sciences
 
Alexander Gold - CAEV Literature Review for Industry
Alexander Gold - CAEV Literature Review for IndustryAlexander Gold - CAEV Literature Review for Industry
Alexander Gold - CAEV Literature Review for IndustryAlexander Gold
 
Fmd transmission Uganda Training Course
Fmd transmission Uganda Training CourseFmd transmission Uganda Training Course
Fmd transmission Uganda Training CourseEuFMD
 
Clinical Manifestations of Plasmodium bergheiANKA Infection in Juvenile Mice:...
Clinical Manifestations of Plasmodium bergheiANKA Infection in Juvenile Mice:...Clinical Manifestations of Plasmodium bergheiANKA Infection in Juvenile Mice:...
Clinical Manifestations of Plasmodium bergheiANKA Infection in Juvenile Mice:...AI Publications
 
Dr. Diego Diel - Senecavirus A: Lessons Learned and Future Perspectives
Dr. Diego Diel - Senecavirus A: Lessons Learned and Future PerspectivesDr. Diego Diel - Senecavirus A: Lessons Learned and Future Perspectives
Dr. Diego Diel - Senecavirus A: Lessons Learned and Future PerspectivesJohn Blue
 
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...John Blue
 
Rotavirus prevention and control
Rotavirus prevention and controlRotavirus prevention and control
Rotavirus prevention and controlSimba Takuva
 
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne Infections
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne InfectionsDr. Robert Tauxe - Public Health Concerns About Resistant Foodborne Infections
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne InfectionsJohn Blue
 
Management of Fungal Infection with Voriconazole Ppt.pptx
Management of Fungal Infection with Voriconazole Ppt.pptxManagement of Fungal Infection with Voriconazole Ppt.pptx
Management of Fungal Infection with Voriconazole Ppt.pptxYuliaDjatiwardani2
 
Covid19 emerging data and guidance
Covid19 emerging data and guidanceCovid19 emerging data and guidance
Covid19 emerging data and guidanceAhmed Al Montasir
 
02 perreul relu 13 avril soir
02 perreul relu 13 avril soir02 perreul relu 13 avril soir
02 perreul relu 13 avril soirMerial EMEA
 
02 perreul relu 13 avril soir
02 perreul relu 13 avril soir02 perreul relu 13 avril soir
02 perreul relu 13 avril soirMerial EMEA
 
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...John Blue
 
Dr. Bob Nordgren - Mucosal Vaccination Principles & Practices
Dr. Bob Nordgren - Mucosal Vaccination Principles & PracticesDr. Bob Nordgren - Mucosal Vaccination Principles & Practices
Dr. Bob Nordgren - Mucosal Vaccination Principles & PracticesJohn Blue
 
Arthropod Borne Diseases.pdf
Arthropod Borne Diseases.pdfArthropod Borne Diseases.pdf
Arthropod Borne Diseases.pdfMandar Baviskar
 

Ähnlich wie 01 sergio lopez soria (20)

Hiv aids general consideration bangladesh and international prospective new
Hiv aids general consideration  bangladesh and international prospective newHiv aids general consideration  bangladesh and international prospective new
Hiv aids general consideration bangladesh and international prospective new
 
Emerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
Emerging Viral Risks and Mitigation Strategies in Biologics ManufacturingEmerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
Emerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
 
Emerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
Emerging Viral Risks and Mitigation Strategies in Biologics ManufacturingEmerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
Emerging Viral Risks and Mitigation Strategies in Biologics Manufacturing
 
Alexander Gold - CAEV Literature Review for Industry
Alexander Gold - CAEV Literature Review for IndustryAlexander Gold - CAEV Literature Review for Industry
Alexander Gold - CAEV Literature Review for Industry
 
Fmd transmission Uganda Training Course
Fmd transmission Uganda Training CourseFmd transmission Uganda Training Course
Fmd transmission Uganda Training Course
 
Clinical Manifestations of Plasmodium bergheiANKA Infection in Juvenile Mice:...
Clinical Manifestations of Plasmodium bergheiANKA Infection in Juvenile Mice:...Clinical Manifestations of Plasmodium bergheiANKA Infection in Juvenile Mice:...
Clinical Manifestations of Plasmodium bergheiANKA Infection in Juvenile Mice:...
 
Dr. Diego Diel - Senecavirus A: Lessons Learned and Future Perspectives
Dr. Diego Diel - Senecavirus A: Lessons Learned and Future PerspectivesDr. Diego Diel - Senecavirus A: Lessons Learned and Future Perspectives
Dr. Diego Diel - Senecavirus A: Lessons Learned and Future Perspectives
 
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
 
Rotavirus prevention and control
Rotavirus prevention and controlRotavirus prevention and control
Rotavirus prevention and control
 
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne Infections
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne InfectionsDr. Robert Tauxe - Public Health Concerns About Resistant Foodborne Infections
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne Infections
 
Management of Fungal Infection with Voriconazole Ppt.pptx
Management of Fungal Infection with Voriconazole Ppt.pptxManagement of Fungal Infection with Voriconazole Ppt.pptx
Management of Fungal Infection with Voriconazole Ppt.pptx
 
Covid19 emerging data and guidance
Covid19 emerging data and guidanceCovid19 emerging data and guidance
Covid19 emerging data and guidance
 
02 perreul relu 13 avril soir
02 perreul relu 13 avril soir02 perreul relu 13 avril soir
02 perreul relu 13 avril soir
 
02 perreul relu 13 avril soir
02 perreul relu 13 avril soir02 perreul relu 13 avril soir
02 perreul relu 13 avril soir
 
02 perreul
02 perreul 02 perreul
02 perreul
 
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
Dr. Michael Murtaugh and Dr. Cheryl Dvorak - Natural Infection, Immunity & Pr...
 
2019-nCoV
2019-nCoV2019-nCoV
2019-nCoV
 
Dr. Bob Nordgren - Mucosal Vaccination Principles & Practices
Dr. Bob Nordgren - Mucosal Vaccination Principles & PracticesDr. Bob Nordgren - Mucosal Vaccination Principles & Practices
Dr. Bob Nordgren - Mucosal Vaccination Principles & Practices
 
EPIDEMIOLOGY OF HIV.pptx
EPIDEMIOLOGY OF HIV.pptxEPIDEMIOLOGY OF HIV.pptx
EPIDEMIOLOGY OF HIV.pptx
 
Arthropod Borne Diseases.pdf
Arthropod Borne Diseases.pdfArthropod Borne Diseases.pdf
Arthropod Borne Diseases.pdf
 

Mehr von Merial EMEA

VAXXITEK HVT + IBD - Field Study - Spain - Merial
VAXXITEK HVT + IBD - Field Study - Spain - MerialVAXXITEK HVT + IBD - Field Study - Spain - Merial
VAXXITEK HVT + IBD - Field Study - Spain - MerialMerial EMEA
 
VAXXITEK HVT + IBD - Field Study - Brazil - Merial
VAXXITEK HVT + IBD - Field Study - Brazil - MerialVAXXITEK HVT + IBD - Field Study - Brazil - Merial
VAXXITEK HVT + IBD - Field Study - Brazil - MerialMerial EMEA
 
VAXXITEK HVT + IBD - Field Study - Egypt - Merial
VAXXITEK HVT + IBD - Field Study - Egypt - MerialVAXXITEK HVT + IBD - Field Study - Egypt - Merial
VAXXITEK HVT + IBD - Field Study - Egypt - MerialMerial EMEA
 
VAXXITEK HVT + IBD - Field Study - China - Merial
VAXXITEK HVT + IBD - Field Study - China - MerialVAXXITEK HVT + IBD - Field Study - China - Merial
VAXXITEK HVT + IBD - Field Study - China - MerialMerial EMEA
 
VAXXITEK HVT + IBD - Field Study - United Kingdom - Merial
VAXXITEK HVT + IBD - Field Study - United Kingdom - MerialVAXXITEK HVT + IBD - Field Study - United Kingdom - Merial
VAXXITEK HVT + IBD - Field Study - United Kingdom - MerialMerial EMEA
 
VAXXITEK HVT + IBD - Field Study - France - Merial
VAXXITEK HVT + IBD - Field Study - France - MerialVAXXITEK HVT + IBD - Field Study - France - Merial
VAXXITEK HVT + IBD - Field Study - France - MerialMerial EMEA
 
Apvs2013 09 vosloo et al.-o1 manisa efficacy vs viet fmd strain in pig
Apvs2013 09 vosloo et al.-o1 manisa efficacy vs viet fmd strain in pigApvs2013 09 vosloo et al.-o1 manisa efficacy vs viet fmd strain in pig
Apvs2013 09 vosloo et al.-o1 manisa efficacy vs viet fmd strain in pigMerial EMEA
 
Apvs2013 04 kagawa et al.-importance of continuation of pcv2 sow vaccination ...
Apvs2013 04 kagawa et al.-importance of continuation of pcv2 sow vaccination ...Apvs2013 04 kagawa et al.-importance of continuation of pcv2 sow vaccination ...
Apvs2013 04 kagawa et al.-importance of continuation of pcv2 sow vaccination ...Merial EMEA
 
Chapat et al.-orf1 et orf2 cmi with CIRCOVAC vaccination in sows
Chapat et al.-orf1 et orf2 cmi with CIRCOVAC vaccination in sowsChapat et al.-orf1 et orf2 cmi with CIRCOVAC vaccination in sows
Chapat et al.-orf1 et orf2 cmi with CIRCOVAC vaccination in sowsMerial EMEA
 
Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality...
Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality...Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality...
Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality...Merial EMEA
 
Apvs2013 01 merdy et al.-circovac pmr calculation
Apvs2013 01 merdy et al.-circovac pmr calculationApvs2013 01 merdy et al.-circovac pmr calculation
Apvs2013 01 merdy et al.-circovac pmr calculationMerial EMEA
 
Apvs2013 10 lee et al.-trypanosomiasis in pigs in malaysia
Apvs2013 10 lee et al.-trypanosomiasis in pigs in malaysiaApvs2013 10 lee et al.-trypanosomiasis in pigs in malaysia
Apvs2013 10 lee et al.-trypanosomiasis in pigs in malaysiaMerial EMEA
 
Apvs2013 08 tee et al.-csf test kit comparison
Apvs2013 08 tee et al.-csf test kit comparisonApvs2013 08 tee et al.-csf test kit comparison
Apvs2013 08 tee et al.-csf test kit comparisonMerial EMEA
 
Apvs2013 07 tonelli and galuppini- serological survey of akipor mixed with gr...
Apvs2013 07 tonelli and galuppini- serological survey of akipor mixed with gr...Apvs2013 07 tonelli and galuppini- serological survey of akipor mixed with gr...
Apvs2013 07 tonelli and galuppini- serological survey of akipor mixed with gr...Merial EMEA
 
Salvini et al.-Introduction of prssv vaccination with PROGRESSIS® in an itali...
Salvini et al.-Introduction of prssv vaccination with PROGRESSIS® in an itali...Salvini et al.-Introduction of prssv vaccination with PROGRESSIS® in an itali...
Salvini et al.-Introduction of prssv vaccination with PROGRESSIS® in an itali...Merial EMEA
 
Apvs2013 06 castellan et al.-clinical case report of h1 n1pdm in italy
Apvs2013 06 castellan et al.-clinical case report of h1 n1pdm in italyApvs2013 06 castellan et al.-clinical case report of h1 n1pdm in italy
Apvs2013 06 castellan et al.-clinical case report of h1 n1pdm in italyMerial EMEA
 
Vila et al. Improvement of herd performance parameters after sow and piglet v...
Vila et al. Improvement of herd performance parameters after sow and piglet v...Vila et al. Improvement of herd performance parameters after sow and piglet v...
Vila et al. Improvement of herd performance parameters after sow and piglet v...Merial EMEA
 
Aasv2014 daresta et al. comparative pcv2 fetal protection-poster
Aasv2014 daresta et al. comparative pcv2 fetal protection-posterAasv2014 daresta et al. comparative pcv2 fetal protection-poster
Aasv2014 daresta et al. comparative pcv2 fetal protection-posterMerial EMEA
 
Aasv2014 callen et al. vaccination compliance to pcv2 using a dth test
Aasv2014 callen et al. vaccination compliance to pcv2 using a dth testAasv2014 callen et al. vaccination compliance to pcv2 using a dth test
Aasv2014 callen et al. vaccination compliance to pcv2 using a dth testMerial EMEA
 
ESPHM 2014 MERIAL momentum cover
ESPHM 2014 MERIAL momentum coverESPHM 2014 MERIAL momentum cover
ESPHM 2014 MERIAL momentum coverMerial EMEA
 

Mehr von Merial EMEA (20)

VAXXITEK HVT + IBD - Field Study - Spain - Merial
VAXXITEK HVT + IBD - Field Study - Spain - MerialVAXXITEK HVT + IBD - Field Study - Spain - Merial
VAXXITEK HVT + IBD - Field Study - Spain - Merial
 
VAXXITEK HVT + IBD - Field Study - Brazil - Merial
VAXXITEK HVT + IBD - Field Study - Brazil - MerialVAXXITEK HVT + IBD - Field Study - Brazil - Merial
VAXXITEK HVT + IBD - Field Study - Brazil - Merial
 
VAXXITEK HVT + IBD - Field Study - Egypt - Merial
VAXXITEK HVT + IBD - Field Study - Egypt - MerialVAXXITEK HVT + IBD - Field Study - Egypt - Merial
VAXXITEK HVT + IBD - Field Study - Egypt - Merial
 
VAXXITEK HVT + IBD - Field Study - China - Merial
VAXXITEK HVT + IBD - Field Study - China - MerialVAXXITEK HVT + IBD - Field Study - China - Merial
VAXXITEK HVT + IBD - Field Study - China - Merial
 
VAXXITEK HVT + IBD - Field Study - United Kingdom - Merial
VAXXITEK HVT + IBD - Field Study - United Kingdom - MerialVAXXITEK HVT + IBD - Field Study - United Kingdom - Merial
VAXXITEK HVT + IBD - Field Study - United Kingdom - Merial
 
VAXXITEK HVT + IBD - Field Study - France - Merial
VAXXITEK HVT + IBD - Field Study - France - MerialVAXXITEK HVT + IBD - Field Study - France - Merial
VAXXITEK HVT + IBD - Field Study - France - Merial
 
Apvs2013 09 vosloo et al.-o1 manisa efficacy vs viet fmd strain in pig
Apvs2013 09 vosloo et al.-o1 manisa efficacy vs viet fmd strain in pigApvs2013 09 vosloo et al.-o1 manisa efficacy vs viet fmd strain in pig
Apvs2013 09 vosloo et al.-o1 manisa efficacy vs viet fmd strain in pig
 
Apvs2013 04 kagawa et al.-importance of continuation of pcv2 sow vaccination ...
Apvs2013 04 kagawa et al.-importance of continuation of pcv2 sow vaccination ...Apvs2013 04 kagawa et al.-importance of continuation of pcv2 sow vaccination ...
Apvs2013 04 kagawa et al.-importance of continuation of pcv2 sow vaccination ...
 
Chapat et al.-orf1 et orf2 cmi with CIRCOVAC vaccination in sows
Chapat et al.-orf1 et orf2 cmi with CIRCOVAC vaccination in sowsChapat et al.-orf1 et orf2 cmi with CIRCOVAC vaccination in sows
Chapat et al.-orf1 et orf2 cmi with CIRCOVAC vaccination in sows
 
Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality...
Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality...Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality...
Apvs2013 02 merdy et al.-comparison circovac vs competitors on adwg mortality...
 
Apvs2013 01 merdy et al.-circovac pmr calculation
Apvs2013 01 merdy et al.-circovac pmr calculationApvs2013 01 merdy et al.-circovac pmr calculation
Apvs2013 01 merdy et al.-circovac pmr calculation
 
Apvs2013 10 lee et al.-trypanosomiasis in pigs in malaysia
Apvs2013 10 lee et al.-trypanosomiasis in pigs in malaysiaApvs2013 10 lee et al.-trypanosomiasis in pigs in malaysia
Apvs2013 10 lee et al.-trypanosomiasis in pigs in malaysia
 
Apvs2013 08 tee et al.-csf test kit comparison
Apvs2013 08 tee et al.-csf test kit comparisonApvs2013 08 tee et al.-csf test kit comparison
Apvs2013 08 tee et al.-csf test kit comparison
 
Apvs2013 07 tonelli and galuppini- serological survey of akipor mixed with gr...
Apvs2013 07 tonelli and galuppini- serological survey of akipor mixed with gr...Apvs2013 07 tonelli and galuppini- serological survey of akipor mixed with gr...
Apvs2013 07 tonelli and galuppini- serological survey of akipor mixed with gr...
 
Salvini et al.-Introduction of prssv vaccination with PROGRESSIS® in an itali...
Salvini et al.-Introduction of prssv vaccination with PROGRESSIS® in an itali...Salvini et al.-Introduction of prssv vaccination with PROGRESSIS® in an itali...
Salvini et al.-Introduction of prssv vaccination with PROGRESSIS® in an itali...
 
Apvs2013 06 castellan et al.-clinical case report of h1 n1pdm in italy
Apvs2013 06 castellan et al.-clinical case report of h1 n1pdm in italyApvs2013 06 castellan et al.-clinical case report of h1 n1pdm in italy
Apvs2013 06 castellan et al.-clinical case report of h1 n1pdm in italy
 
Vila et al. Improvement of herd performance parameters after sow and piglet v...
Vila et al. Improvement of herd performance parameters after sow and piglet v...Vila et al. Improvement of herd performance parameters after sow and piglet v...
Vila et al. Improvement of herd performance parameters after sow and piglet v...
 
Aasv2014 daresta et al. comparative pcv2 fetal protection-poster
Aasv2014 daresta et al. comparative pcv2 fetal protection-posterAasv2014 daresta et al. comparative pcv2 fetal protection-poster
Aasv2014 daresta et al. comparative pcv2 fetal protection-poster
 
Aasv2014 callen et al. vaccination compliance to pcv2 using a dth test
Aasv2014 callen et al. vaccination compliance to pcv2 using a dth testAasv2014 callen et al. vaccination compliance to pcv2 using a dth test
Aasv2014 callen et al. vaccination compliance to pcv2 using a dth test
 
ESPHM 2014 MERIAL momentum cover
ESPHM 2014 MERIAL momentum coverESPHM 2014 MERIAL momentum cover
ESPHM 2014 MERIAL momentum cover
 

Kürzlich hochgeladen

MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxAnupkumar Sharma
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4MiaBumagat1
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)lakshayb543
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfSpandanaRallapalli
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPCeline George
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Mark Reed
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17Celine George
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Jisc
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomnelietumpap1
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxMaryGraceBautista27
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
Q4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxQ4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxnelietumpap1
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptxmary850239
 

Kürzlich hochgeladen (20)

Raw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptxRaw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptx
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdf
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptxYOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERP
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choom
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptx
 
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptxYOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
Q4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxQ4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptx
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx
 

01 sergio lopez soria

  • 1.  
  • 2. Sergio López Soria PCVD in 2011: An update
  • 3. Historical background of PCV2 and PCVD
  • 4.
  • 5.
  • 6.
  • 7.
  • 9.
  • 10.
  • 11.
  • 12. 1960 2009 Natural history of PCV2 and PMWS First retrospective evidence of PCV2 infection (1962) First retrospective evidence of PMWS occurrence (1985) First description of PMWS in NA (1991) – sporadic First description of PMWS in EU (1995-97) Major epizootic PMWS outbreaks in EU and Asia (1998-2004) Major epizootic PMWS outbreaks in North and South America (2004-07) First PCV2 vaccine available (2004) PCV2 vaccines
  • 13.
  • 14. PCV2 infection and transmission
  • 15. PCV2 viral loads (qPCR) or PCV2 antibody titres Weeks of age PCV2 antibodies PMWS PCV2 infection dynamics 1 3 7-9 21 15 PCV2 viremia
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21. PMWS
  • 22. If PCV2 is ubiquitous, ¿WHY SOME FARMS EXPERIENCE PMWS?
  • 23. Pig genetics, sex, other Co-infections PCV2 genotype Moment of infection Sow status Management: Madec’s 20 point plan PMWS: a multifactorial disease
  • 24.
  • 25. PMWS reduction through zootechnical measures (Guilmoto y Wessel-Robert, 2000) Farm Rate of measures compliance Loss rate before (%) Loss reduction 1 81% 18.3 -13.7 2 86% 14.7 -12.7 3 59% 19.0 -9.3 4 84% 11.2 -5.8 5 79% 15.3 -6.4 6 70% 12.7 -4.7 7 82% 11.5 -4.4 8 55% 12.3 -3.5 9 54% 17.6 0.4 10 72% 11.3 0.7 Media 66% 13.1 -5.4
  • 26. PMWS reduction through zootechnical measures (Guilmoto y Wessel-Robert, 2000) Farm Rate of measures compliance Loss rate before (%) Loss reduction 1 81% 18.3 -13.7 2 86% 14.7 -12.7 3 59% 19.0 -9.3 4 84% 11.2 -5.8 5 79% 15.3 -6.4 6 70% 12.7 -4.7 7 82% 11.5 -4.4 8 55% 12.3 -3.5 9 54% 17.6 0.4 10 72% 11.3 0.7 Media 66% 13.1 -5.4
  • 27.
  • 28.
  • 29.
  • 31. PCV2 subclinical infection 160 piglets from two PMWS affected farms. Weight and viral load analyses at 3, 9, 15 and 21 wks of age. Area under the curve for weight and viral load was calculated. The higher the AUCqPCR during the postweaning period, the lower AUCW (ρ=-0.203; p=0.010).
  • 33. PCR Laboratorial Analyses: PCR Useful to monitor: Infection dynamic Subclinical infection Sibila et al., 2004 % PCR (serum) Weeks of age Non-PMWS affected farms Percentage PMWS affected farms PCV2 is ubiquitous Not useful for PMWS diagnosis
  • 34. Can PMWS be diagnosed in live animals??? Laboratorial Analyses: qPCR Quantitative PCR Slight Moderate Severe PMWS lesions a b c Olvera et al., 2004 PMWS Subclinical PCV2 infection
  • 35. Not proved to be specific and/or sensitive enough to replace current diagnostic criteria (Fort et al., 2007; Grau-Roma et al., 2009) Inter-laboratory and inter-assay variation (Harding et al., 2009; Hjulsager et al., 2009) qPCR suggested applications for PMWS herd diagnosis. Can qPCR be used as a diagnostic tool for PMWS?
  • 36. Non-PMWS affected farms Weeks of age PMWS affected farms Serology (IPMA, ELISA) Sibila et al., 2004 Percentage Laboratorial Analyses: Serology Useful to monitor: Maternal immunity transfer Infection dynamic Seroconversion to vaccination PCV2 is ubiquitous All piglets seroconvert Not useful for PMWS diagnosis
  • 37.
  • 38.
  • 40. Prevention and control Prevention and control Initial efforts directed to counteract the known triggering factors Since 2004 onwards  PCV2 vaccination
  • 41.
  • 43.  

Hinweis der Redaktion

  1. Aquí tenemos dos ejemplos de la dinámica de infección (PCR) y el perfil serológico de animales procedentes de granjas con (en verde) y sin CP (en amarillo). Como podeis ver tanto las granjas con CP como las sin CP estan infectadas con el virus, aunque las que sufren la enfermedad tiene un mayor porcentage de animles infectados. En cuanto a la serología, vemos que no diferencias en el perfil serológico entre granjas con y sin CP